Renal Cell Carcinoma
Systemic therapy for mRCC: second line and beyondGustavo (67 years old)
Gustavo, 67 years old, is a retired financial advisor. Nowadays, he is helping his whole neighbourhood obtain the biggest tax return possible. He was diagnosed with primary metastatic renal cell carcinoma (mRCC) 4 years ago.
Assessment summary 4 years ago:
- Metastatic sites: lung, bone, lymph nodes and adrenal gland
- No relevant past medical history
- International mRCC Database Consortium (IMDC): intermediate risk
- Biopsy of bone: histologically confirmed metastasis of clear-cell RCC (ccRCC)
Underwent laparoscopic cytoreductive nephrectomy on the right side 4 years ago:
- pT2a, no lymphatic or venous invasion, no residual tumour
- Grade 3 ccRCC
First-line therapy with sunitinib (50 mg/day) on a ‘4 weeks on, 2 weeks off’ schedule was initiated shortly thereafter.
Now, 4 years later: disease progression, metastatic sites: lung, bone, lymph nodes and adrenal gland.